Post by icemandios on Sept 3, 2021 12:47:46 GMT
Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th
PR Newswire
MARLBOROUGH, Mass. , Sept. 3, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL ™ ) therapeutic platform, today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 to 15, 2021 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Phio Company Presentation Details:
Speaker: Dr. Gerrit Dispersyn, President & CEO of Phio Pharmaceuticals
Time/Date: Available starting at 7:00 AM ET on Monday, September 13 th
Webcast: Registration ( Click Here )
Replay: Interested parties may also access a replay of the Company presentation through the "Investors – Events and Presentations" section of the Company's website ( click here) . The webcast will be archived and available on the Company's website for 90 days.
For more information on the conference, or to schedule a one-on-one meeting, please contact a H.C. Wainwright representative.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL ™ ) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com
PR Newswire
MARLBOROUGH, Mass. , Sept. 3, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL ™ ) therapeutic platform, today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 to 15, 2021 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Phio Company Presentation Details:
Speaker: Dr. Gerrit Dispersyn, President & CEO of Phio Pharmaceuticals
Time/Date: Available starting at 7:00 AM ET on Monday, September 13 th
Webcast: Registration ( Click Here )
Replay: Interested parties may also access a replay of the Company presentation through the "Investors – Events and Presentations" section of the Company's website ( click here) . The webcast will be archived and available on the Company's website for 90 days.
For more information on the conference, or to schedule a one-on-one meeting, please contact a H.C. Wainwright representative.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL ™ ) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com